Rhythm Pharmaceuticals (RYTM) Expected to Release Earnings on Tuesday

Rhythm Pharmaceuticals (NASDAQ:RYTM) will likely be announcing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Rhythm Pharmaceuticals to announce earnings of ($0.7101) per share and revenue of $85.47 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its earnings results on Tuesday, August 4th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.08. The business had revenue of $71.25 million during the quarter, compared to the consensus estimate of $67.66 million. Rhythm Pharmaceuticals had a negative return on equity of 159.87% and a negative net margin of 85.59%. The firm’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.75) earnings per share. On average, analysts expect Rhythm Pharmaceuticals to post ($2.77) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Rhythm Pharmaceuticals Stock Performance

Shares of RYTM stock opened at $89.47 on Tuesday. Rhythm Pharmaceuticals has a fifty-two week low of $74.50 and a fifty-two week high of $122.20. The stock has a 50 day simple moving average of $98.89 and a two-hundred day simple moving average of $97.54. The company has a market cap of $6.13 billion, a P/E ratio of -28.77 and a beta of 2.01.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, EVP Jennifer Lee sold 75,834 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $117.38, for a total transaction of $8,901,394.92. Following the completion of the sale, the executive vice president owned 54,233 shares in the company, valued at approximately $6,365,869.54. This represents a 58.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO David Meeker sold 50,000 shares of Rhythm Pharmaceuticals stock in a transaction on Monday, September 14th. The stock was sold at an average price of $102.67, for a total transaction of $5,133,500.00. Following the transaction, the chief executive officer directly owned 239,258 shares in the company, valued at $24,564,618.86. This represents a 17.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 258,450 shares of company stock valued at $28,796,497 in the last three months. Insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on RYTM. JPMorgan Chase & Co. reduced their price objective on shares of Rhythm Pharmaceuticals from $146.00 to $145.00 and set an “overweight” rating for the company in a research report on Thursday, October 15th. HC Wainwright lifted their price target on shares of Rhythm Pharmaceuticals from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Citizens Jmp lifted their price target on shares of Rhythm Pharmaceuticals from $155.00 to $160.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada upped their price target on Rhythm Pharmaceuticals from $155.00 to $159.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Eighteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $142.50.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity and related metabolic disorders. The company’s work is based on the melanocortin-4 receptor (MC4R) pathway, which plays an important role in regulating hunger and energy balance.

Rhythm’s principal product is IMCIVREE (setmelanotide), a targeted therapy designed to restore impaired MC4R pathway signaling. In the United States, IMCIVREE is approved for chronic weight management in adults and children at least 6 years old with obesity caused by certain genetic deficiencies, including POMC, PCSK1, or LEPR deficiency, as well as Bardet-Biedl syndrome.